Why the study?
Does mitoxantrone improve tumor response in women with relapsed breast cancer after adjuvant CMF?
Does mitoxantrone improve tumor response in women with relapsed breast cancer after adjuvant CMF?
Mitoxantrone provides a 28% response rate as first-salvage chemotherapy in relapsed breast cancer with manageable toxicity and no clinical congestive heart failure.
No takes yet. Share an insight, caveat, or question.
May support salvage consideration in relapsed breast cancer; case-report data leave open need for randomized confirmation.
Brambilla et al. (1989) studied this question.